Pharma Running Up Against Deadline for Assessing Excipient Risks
This article was originally published in The Gold Sheet
Pharmaceutical manufacturers may not have enough time to comply with the EU’s new risk assessment guideline, which goes into effect early next year. The magnitude of the task involved in evaluating excipient risk poses a challenge for the pharmaceutical industry and excipient makers alike.
You may also be interested in...
Action responds to methanol contamination in hand sanitizers manufactured in Mexico and marketed in the US under numerous brands that followed a loosening standards for the products to drive a swift increase in production and meet surging demand during the coronavirus pandemic.
New import alert category and border testing required after reduced standards put dangerous sanitizers into hands of US consumers.
New COVID-19 Vaccines May Be Accelerated By Using Existing Manufacturing Platforms, US FDA's Marks Says
FDA's CBER director says the development of new COVID-19 vaccines can be accelerated by using manufacturing platforms developed for other types of vaccines, thereby reducing the need for product-specific data.